These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33460301)

  • 1. Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype.
    Goodman AD; Fedler JK; Yankey J; Klingner EA; Ecklund DJ; Goebel CV; Bermel RA; Chase M; Coffey CS; Klawiter EC; Naismith RT; Fox RJ;
    Ann Clin Transl Neurol; 2021 Jan; 8(1):111-118. PubMed ID: 33460301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post Hoc Analyses of the SPRINT-MS Trial.
    Ehrhardt H; Lambe J; Moussa H; Vasileiou ES; Kalaitzidis G; Murphy OC; Filippatou AG; Pellegrini N; Douglas M; Davis S; Nagy N; Quiroga A; Hu C; Zambriczki Lee A; Duval A; Fitzgerald KC; Prince JL; Calabresi PA; Sotirchos ES; Bermel R; Saidha S
    Neurology; 2023 Sep; 101(10):e1014-e1024. PubMed ID: 37460235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
    Fox RJ; Coffey CS; Conwit R; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Naismith RT; Ashokkumar A; Barnes J; Ecklund D; Klingner E; Koepp M; Long JD; Natarajan S; Thornell B; Yankey J; Bermel RA; Debbins JP; Huang X; Jagodnik P; Lowe MJ; Nakamura K; Narayanan S; Sakaie KE; Thoomukuntla B; Zhou X; Krieger S; Alvarez E; Apperson M; Bashir K; Cohen BA; Coyle PK; Delgado S; Dewitt LD; Flores A; Giesser BS; Goldman MD; Jubelt B; Lava N; Lynch SG; Moses H; Ontaneda D; Perumal JS; Racke M; Repovic P; Riley CS; Severson C; Shinnar S; Suski V; Weinstock-Guttman B; Yadav V; Zabeti A;
    N Engl J Med; 2018 Aug; 379(9):846-855. PubMed ID: 30157388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis.
    Ladakis DC; Reyes-Mantilla MI; Gadani SP; Mace JW; Dominguez-Penuela SC; Appiah MJ; Smith MD; Bhargava P; Fox RJ; Saidha S; Calabresi PA
    Mult Scler; 2024 Jan; 30(1):35-43. PubMed ID: 37982154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Leppert D; Kropshofer H; Häring DA; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
    Neurology; 2022 May; 98(21):e2120-e2131. PubMed ID: 35379762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
    Fox RJ; Coffey CS; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Conwit R; Naismith R; Ashokkumar A; Bermel R; Ecklund D; Koepp M; Long J; Natarajan S; Ramachandran S; Skaramagas T; Thornell B; Yankey J; Agius M; Bashir K; Cohen B; Coyle P; Delgado S; Dewitt D; Flores A; Giesser B; Goldman M; Jubelt B; Lava N; Lynch S; Miravalle A; Moses H; Ontaneda D; Perumal J; Racke M; Repovic P; Riley C; Severson C; Shinnar S; Suski V; Weinstock-Gutman B; Yadav V; Zabeti A
    Contemp Clin Trials; 2016 Sep; 50():166-77. PubMed ID: 27521810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
    Nicholson S; Russo AW; Brewer K; Bien H; Tobyne SM; Eloyan A; Klawiter EC
    Mult Scler; 2023 Dec; 29(14):1819-1830. PubMed ID: 37947294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
    Nakamura K; Zheng Y; Mahajan KR; Cohen JA; Fox RJ; Ontaneda D
    Mult Scler; 2023 Sep; 29(10):1257-1265. PubMed ID: 37537928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K
    Mult Scler; 2019 Jun; 25(7):947-957. PubMed ID: 29781383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.
    Naismith RT; Bermel RA; Coffey CS; Goodman AD; Fedler J; Kearney M; Klawiter EC; Nakamura K; Narayanan S; Goebel C; Yankey J; Klingner E; Fox RJ;
    Neurology; 2021 Jan; 96(4):e491-e500. PubMed ID: 33268562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis.
    Giovannoni G; Knappertz V; Steinerman JR; Tansy AP; Li T; Krieger S; Uccelli A; Uitdehaag BMJ; Montalban X; Hartung HP; Pia Sormani M; Cree BAC; Lublin F; Barkhof F
    Neurology; 2020 Aug; 95(8):e1027-e1040. PubMed ID: 32651286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis.
    Laule C; Vavasour IM; Zhao Y; Traboulsee AL; Oger J; Vavasour JD; Mackay AL; Li DK
    Mult Scler; 2010 Jun; 16(6):670-7. PubMed ID: 20558500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
    Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
    Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
    Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
    Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
    Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical cord lesion load is associated with disability independently from atrophy in MS.
    Kearney H; Altmann DR; Samson RS; Yiannakas MC; Wheeler-Kingshott CA; Ciccarelli O; Miller DH
    Neurology; 2015 Jan; 84(4):367-73. PubMed ID: 25540312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of cytotoxic Eomes-expressing CD4
    Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
    Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
    Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O; Gouveia A; Batista S; Moura C; Machado E
    Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.